Anaemia is a frequent complication of chronic kidney disease (CKD) that is associated with reduced quality of life and adverse clinical outcomes. A new analysis suggests that the global burden of anaemia in CKD will rise substantially in the next 25 years.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048–1050 (2019).
Li, Y. et al. Global, regional, and national burden of renal anemia, 1990 to 2019 and prediction to 2050. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfaf102 (2025).
Deng, L. et al. Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health 25, 636 (2025).
Foreman, K. J. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 392, 2052–2090 (2018).
Francis, A. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat. Rev. Nephrol. 20, 473–485 (2024).
Safiri, S. et al. Burden of anemia and its underlying causes in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. J. Hematol. Oncol. 14, 185 (2021).
GBD 2021 Anaemia Collaborators. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021. Lancet Haematol. 10, e713–e734 (2023).
Sugahara, M., Tanaka, T. & Nangaku, M. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. Pharmacol. Ther. 239, 108272 (2022).
Babitt, J. L. et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference. Kidney Int. 99, 1280–1295 (2021).
Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584–590 (1998).
Acknowledgements
The authors’ work was supported by MEXT/JSPS grant-in-aids 24K11425 (to H.N.) and 23K27615 (to M.N.), and AMED grant 22zf0127006h0001 (to M.N.). The funders had no role in manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.N. reports receiving honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Kowa, Kyowa Kirin, Mitsubishi Tanabe, MSD, Ono, Otsuka and Torii; and research grants from Bayer, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe and Novo Nordisk. M.N. reports receiving honoraria and/or advisory fees from Astellas, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, GSK, JT, Kyowa Kirin, Mitsubishi Tanabe, Novo Nordisk and Torii; and research grants from Astellas, Bayer, Chugai, Daiichi Sankyo, JT, Kyowa Kirin, Mitsubishi Tanabe, Ono, Takeda and Torii.
Rights and permissions
About this article
Cite this article
Nishi, H., Nangaku, M. The increasing burden of mild and moderate anaemia in CKD. Nat Rev Nephrol 21, 651–652 (2025). https://doi.org/10.1038/s41581-025-00994-7
Published:
Issue date:
DOI: https://doi.org/10.1038/s41581-025-00994-7
